Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Bergethon K, Shaw AT, Ou S-HI, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–870. doi:10.1200/JCO.2011.35.634522215748
   PubMed Web of Science ®Google Scholar
• Rossi G, Jocollé G, Conti A, et al. Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives. Lung Cancer (Auckl). 2017;8:45–55. doi:10.2147/LCTT.S12017228740441
   PubMed Web of Science ®Google Scholar
• Supplee JG, Milan MSD, Lim LP, et al. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. Lung Cancer. 2019;134:96–99. doi:10.1016/j.lungcan.2019.06.00431320002
   PubMed Web of Science ®Google Scholar
• Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non–small cell lung cancer. Clin Cancer Res. 2019;25(15):4691–4700. doi:10.1158/1078-0432.CCR-19-062430988079
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971. doi:10.1056/NEJMoa140676625264305
   PubMed Web of Science ®Google Scholar
• Shaw AT, Riely GJ, Bang Y-J, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019 Epub ahead of print.
   Web of Science ®Google Scholar
• Liang Y, Wakelee HA, Neal JW. Relationship of driver oncogenes to long-term pemetrexed response in non-small-cell lung cancer. Clin Lung Cancer. 2015;16(5):366–373. doi:10.1016/j.cllc.2014.12.00925665893
   PubMed Web of Science ®Google Scholar
• Chen YF, Hsieh MS, Wu SG, et al. Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations. J Thorac Oncol. 2016;11(7):1140–1152. doi:10.1016/j.jtho.2016.03.02227094798
   PubMed Web of Science ®Google Scholar
• Lim SM, Kim HR, Lee JS, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35(23):2613–2618. doi:10.1200/JCO.2016.71.370128520527
   PubMed Web of Science ®Google Scholar
• Drilon A, Somwar R, Wagner JP, et al. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer. Clin Cancer Res. 2015;22(10):2351–2358. doi:10.1158/1078-0432.CCR-15-201326673800
   PubMed Web of Science ®Google Scholar
• Sun TY, Niu X, Chakraborty A, et al. Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non–small cell lung cancer. J Thorac Oncol. 2019;14(2):e21–e24. doi:10.1016/j.jtho.2018.08.203030217491
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Ou SHI, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400–409. doi:10.1158/2159-8290.CD-16-123728183697
   PubMed Web of Science ®Google Scholar
• Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–1599. doi:10.1016/S1470-2045(17)30072-429074098
   PubMed Web of Science ®Google Scholar
• Ou S, Shaw A, Riely G, et al. OA02.03 Clinical Activity of lorlatinib in patients with ROS1+ advanced non-small cell lung cancer: phase 2 study cohort EXP-6. J Thorac Oncol. 2018;13(suppl_10):S322–S323. doi:10.1016/j.jtho.2018.08.241
   Web of Science ®Google Scholar
• Hegde A, Hong DS, Behrang A, et al. Activity of brigatinib in crizotinib and ceritinib-resistant ROS1-rearranged non–small-cell lung cancer. JCO Precis Oncol. 2019;3:1–6.
   Web of Science ®Google Scholar
• Fujiwara Y, Takeda M, Yamamoto N, et al. Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. Oncotarget. 2018;9(34):23729–23737. doi:10.18632/oncotarget.2526329805770
   PubMedGoogle Scholar
• Drilon A, Ou S-HI, Cho BC, et al. Repotrectinib (TPX-0005) is a next generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent front mutations. Cancer Discov. 2018;8(10):1227–1236. doi:10.1158/2159-8290.CD-18-048430093503
   PubMed Web of Science ®Google Scholar
• Cho BC, Drilon A, Doebele R, et al. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). J Clin Oncol. 2019;37(15_suppl):9011.
   Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Non-Small Cell Lung Cancer (version 2.2019). Available from: https://www.nccn.org/professionals/physician_gls/recently_updated.aspx. Accessed September 3, 2019.
   Google Scholar
• Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol. 2018;15(11):694–708. doi:10.1038/s41571-018-0081-430108370
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc. Accessed August 28, 2019
   Google Scholar
• ESMO. Japan Becomes the First Country to Approve Entrectinib Available from: https://www.esmo.org/Oncology-News/Japan-Becomes-the-First-Country-to-Approve-Entrectinib. Accessed August 28, 2019.
   Google Scholar
• Menichincheri M, Ardini E, Magnaghi P, et al. Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (pan-TRKs) inhibitor. J Med Chem. 2016;59(7):3392–3408. doi:10.1021/acs.jmedchem.6b0006427003761
   PubMed Web of Science ®Google Scholar
• Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013;368(25):2395–2401. doi:10.1056/NEJMoa121553023724914
   PubMed Web of Science ®Google Scholar
• Ardini E, Menichincheri M, Banfi P, et al. Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther. 2016;15(4):628–639. doi:10.1158/1535-7163.MCT-15-075826939704
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Loriot Y, Kuo MS, et al. Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers. Clin Cancer Res. 2016;22(24):5983–5991. doi:10.1158/1078-0432.CCR-16-091727401242
   PubMed Web of Science ®Google Scholar
• Katayama R, Gong B, Togashi N, et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1- G2032R mutation in preclinical models. Nat Commun. 2019;10(1):3604. doi:10.1038/s41467-019-11496-z31399568
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med. 2017;377(9):829–838. doi:10.1056/NEJMoa170479528586279
   PubMed Web of Science ®Google Scholar
• Patil T, Smith DE, Bunn PA, et al. The incidence of brain metastases in stage IV ROS1-rearranged non–small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717–1726. doi:10.1016/j.jtho.2018.07.00129981925
   PubMed Web of Science ®Google Scholar
• Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non–small-cell lung cancer. JCO Precis Oncol. 2017;1:1–13.
   Web of Science ®Google Scholar
• Ku BM, Bae YH, Lee KY, et al. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. Invest New Drugs. 2019 Epub ahead of print. doi:10.1007/s10637-019-00795-3
   PubMed Web of Science ®Google Scholar
• Barlesi F, Drilon A, De Braud F, et al. Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2. Ann Oncol. 2019;30(suppl_2):109O. doi:10.1093/annonc/mdz063.00730357310
   PubMed Web of Science ®Google Scholar
• Ahn M, Cho BC, Siena S, et al. OA 14.06 Entrectinib in patients with locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). J Thorac Oncol. 2017;12(11_suppl):S1783. doi:10.1016/j.jtho.2017.09.411
   Web of Science ®Google Scholar
• Doebele R, Ahn M, Siena S, et al. OA02.01 Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). J Thorac Oncol. 2018;13(suppl_10):S321–S322. doi:10.1016/j.jtho.2018.08.239
   Web of Science ®Google Scholar
• Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018;29(11):2214–2222. doi:10.1093/annonc/mdx80730215676
   PubMed Web of Science ®Google Scholar
• Mazières J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019 Epub ahead of print. doi:10.1093/annonc/mdz167
   Web of Science ®Google Scholar
• Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401. doi:10.1016/S2213-2600(19)30084-030922878
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Rooney M, Nagy RJ, et al. Molecular analysis of plasma from patients with ROS1-positive NSCLC. J Thorac Oncol. 2019;14(15):816–824. doi:10.1016/j.jtho.2019.01.00930664990
   PubMed Web of Science ®Google Scholar
• Zugazagoitia J, Gómez-Rueda A, Jantus-Lewintre E, et al. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Lung Cancer. 2019;134:72–78. doi:10.1016/j.lungcan.2019.05.03231319999
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(28):3375–3382. doi:10.1200/JCO.2016.66.716227354477
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Brannon AR, Ferris LA, et al. Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA. JCO Precis Oncol. 2018;2:1–14.30949620
   PubMed Web of Science ®Google Scholar
• Wu YL, Yang JC, Kim DW, et al. Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(14):1405–1411. doi:10.1200/JCO.2017.75.558729596029
   PubMed Web of Science ®Google Scholar
• Michels S, Massutí B, Schildhaus HU, et al. Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase II clinical trial. J Thorac Oncol. 2019;14(7):1266–1276. doi:10.1016/j.jtho.2019.03.02030978502
   PubMed Web of Science ®Google Scholar
• Landi L, Chiari R, Tiseo M, et al. Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial. Clin Cancer Res. 2019 Epub ahead of print. doi:10.1158/1078-0432.CCR-19-0994
   Web of Science ®Google Scholar